Study on population pharmacokinetic parameters, safety, and effectiveness of remidazolam

Remidazolam blood concentration detection and population pharmacokinetic study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043396

Enrollment

Unknown

Registered

2021-02-13

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Remidazolam:Continuous infusion

Propofol :Continuous infusion

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification: I-III; 2. Aged 18-80 years; 3. Liver and kidney function is normal.

Exclusion criteria

Exclusion criteria: BMI 30, patients with prolonged QT interval on ECG, severe liver and kidney dysfunction, abnormal mental status, etc., who cannot cooperate.

Design outcomes

Primary

Measure	Time frame
blood concentration;	—

Countries

China

Contacts

Public ContactEnyou Li

The First Affiliated Hospital of Harbin Medical University

enyouli@sina.com+86 13845109928

Outcome results